INVESTORS & MEDIA

TARRYTOWN, N.Y., Dec. 20, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time on Monday, December 20, to discuss results of the Phase 3 COPERNICUS study with VEGF Trap-Eye in central retinal vein occlusion (CRVO) and the week 52 follow-up results of the Phase 2 DA VINCI study in patients with diabetic macular edema (DME).  A press release will be issued prior to the call.

Teleconference/Webcast Details

To participate in the live call on Monday, December 20, at 8:30 a.m. Eastern Time, please dial (877) 390-5538 for domestic callers and (408) 940-3843 for international callers, participant code 33105543.  The live conference call is being webcast and it can be accessed on the "Newsroom" page of the Company's web site, www.regeneron.com.  The webcast will be available for 30 days following the call.

About Regeneron Pharmaceuticals

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

SOURCE Regeneron Pharmaceuticals, Inc.